Sp-cAMPS sodium salt

Name: Sp-cAMPS sodium salt
Brand: MedChemExpress
SKU: HY-100530C
Rating: 4.5 (1 reviews)

Cat. No.: HY-100530C Purity: 99.45%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

For research use only. We do not sell to patients.

Sp-cAMPS sodium salt Chemical Structure

CAS No. : 142439-95-0

Size	Price	Stock	Quantity
1 mg	USD 85	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 300	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 510	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1120	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 1900	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 3200	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Sp-cAMPS sodium salt:

Rp-cAMPS triethylammonium salt Get quote
Rp-cAMPS Get quote
Rp-cAMPS sodium salt Get quote
Sp-cAMPS Get quote
Sp-cAMPS triethylamine Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PKA Isoform Specific Products:

View All Isoforms

PKA PKAR

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms

PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]^[3]

PKA I

PKA II

PDE3A

47.6 μM (Ki)

PDE10 GAF domain

50 μM (EC₅₀)

In Vitro

Treatment of hepatocytes with Sp-cAMPS sodium salt, the stimulatory diastereomer of adenosine cyclic 3',5'-phosphorothioate, mimics the response seen with glucagon. The glucagon-stimulated increases in the level of Ca²⁺ can be mimicked by Sp-cAMPS sodium salt^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In chronic alcohol consumption (CAC) mice, direct infusion of the Sp-cAMPS (1 µg/µL) sodium salt into the prefrontal cortex significantly improves or impairs, respectively, working memory performance in withdrawn and water animals^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

367.25

Formula

C₁₀H₁₁N₅NaO₅PS

CAS No.

142439-95-0

Appearance

Solid

Color

White to off-white

SMILES

O[C@H]1[C@@H](O[C@@]2([H])[C@@]1([H])O[P@](OC2)([S])=O)N3C4=C(C(N)=NC=N4)N=C3.[Na+].[-]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (272.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 86.67 mg/mL (236.00 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7229 mL	13.6147 mL	27.2294 mL
5 mM	0.5446 mL	2.7229 mL	5.4459 mL
10 mM	0.2723 mL	1.3615 mL	2.7229 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 50 mg/mL (136.15 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.45%

Select Batch:

Data Sheet (276 KB) SDS (252 KB)

COA (251 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Su H Hung, et al. A new nonhydrolyzable reactive cAMP analog, (Sp)-adenosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase. Bioorg Chem. 2002 Feb;30(1):16-31. [Content Brief]

[2]. L Y Wang, et al. Regulation of kainate receptors by cAMP-dependent protein kinase and phosphatases. Science. 1991 Sep 6;253(5024):1132-5. [Content Brief]

[3]. Ronald Jäger, et al. Activation of PDE10 and PDE11 phosphodiesterases. J Biol Chem. 2012 Jan 6;287(2):1210-9. [Content Brief]

[4]. P A Connelly,et al. A study of the mechanism of glucagon-induced protein phosphorylation in isolated rat hepatocytes using (Sp)-cAMPS and (Rp)-cAMPS, the stimulatory and inhibitory diastereomers of adenosine cyclic 3',5'-phosphorothioate. J Biol Chem. 1987 Mar 25;262(9):4324-32. [Content Brief]

[5]. G Dominguez, et al. Rescuing prefrontal cAMP-CREB pathway reverses working memory deficits during withdrawal from prolonged alcohol exposure. Brain Struct Funct. 2016 Mar;221(2):865-77. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.7229 mL	13.6147 mL	27.2294 mL	68.0735 mL
	5 mM	0.5446 mL	2.7229 mL	5.4459 mL	13.6147 mL
	10 mM	0.2723 mL	1.3615 mL	2.7229 mL	6.8074 mL
	15 mM	0.1815 mL	0.9076 mL	1.8153 mL	4.5382 mL
	20 mM	0.1361 mL	0.6807 mL	1.3615 mL	3.4037 mL
	25 mM	0.1089 mL	0.5446 mL	1.0892 mL	2.7229 mL
	30 mM	0.0908 mL	0.4538 mL	0.9076 mL	2.2691 mL
	40 mM	0.0681 mL	0.3404 mL	0.6807 mL	1.7018 mL
	50 mM	0.0545 mL	0.2723 mL	0.5446 mL	1.3615 mL
	60 mM	0.0454 mL	0.2269 mL	0.4538 mL	1.1346 mL
	80 mM	0.0340 mL	0.1702 mL	0.3404 mL	0.8509 mL
	100 mM	0.0272 mL	0.1361 mL	0.2723 mL	0.6807 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.